$3.08
1.28% day before yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Stock price

$3.08
+0.02 0.65% 1M
-0.44 12.50% 6M
-0.19 5.81% YTD
+0.19 6.57% 1Y
+0.82 36.28% 3Y
+1.21 64.71% 5Y
-10.74 77.71% 10Y
Nasdaq, Closing price Fri, May 16 2025
-0.04 1.28%
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Key metrics

Market capitalization $589.90m
Enterprise Value $482.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 75.44
P/S ratio (TTM) P/S ratio 92.17
P/B ratio (TTM) P/B ratio 7.45
Revenue growth (TTM) Revenue growth -50.69%
Revenue (TTM) Revenue $6.40m
EBIT (operating result TTM) EBIT $-63.82m
Free Cash Flow (TTM) Free Cash Flow $-57.71m
Cash position $112.71m
EPS (TTM) EPS $-0.40
P/E forward negative
P/S forward 101.16
EV/Sales forward 82.79
Short interest 8.30%
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Arbutus Biopharma Corporation forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
75%
Hold
25%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6.40 6.40
51% 51%
100%
- Direct Costs 1.36 1.36
5% 5%
21%
5.05 5.05
56% 56%
79%
- Selling and Administrative Expenses 20 20
3% 3%
311%
- Research and Development Expense 48 48
33% 33%
744%
-62 -62
21% 21%
-976%
- Depreciation and Amortization 1.36 1.36
5% 5%
21%
EBIT (Operating Income) EBIT -64 -64
20% 20%
-997%
Net Profit -77 -77
3% 3%
-1,196%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Neutral
GlobeNewsWire
4 days ago
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon
Neutral
GlobeNewsWire
11 days ago
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER...
Neutral
GlobeNewsWire
25 days ago
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of t...
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Lindsay Androski
Employees 44
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today